Canagliflozin: a sodium glucose co‐transporter 2 inhibitor for the treatment of type 2 diabetes mellitus-Reference-Cited by-同舟云学术

Canagliflozin: a sodium glucose co‐transporter 2 inhibitor for the treatment of type 2 diabetes mellitus

Published:2015-08-25 Issue:1 Volume:1358 Page:28-43
ISSN:0077-8923
Container-title:Annals of the New York Academy of Sciences
language:en
Short-container-title:Ann. N.Y. Acad. Sci.

Author:

Rosenthal Norm¹,Meininger Gary¹,Ways Kirk¹,Polidori David²,Desai Mehul¹,Qiu Rong¹,Alba Maria¹,Vercruysse Frank¹,Balis Dainius¹,Shaw Wayne¹,Edwards Robert¹,Bull Scott³,Di Prospero Nicholas¹,Sha Sue¹,Rothenberg Paul¹,Canovatchel William¹,Demarest Keith¹

Affiliation:

1. Janssen Research & Development LLC Raritan New Jersey

2. Janssen Research & Development LLC San Diego California

3. Janssen Research & Development LLC Fremont California

Funder

Janssen Global Services, LLC

Publisher

Wiley

Subject

History and Philosophy of Science,General Biochemistry, Genetics and Molecular Biology,General Neuroscience

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/nyas.12852

Reference63 articles.

1. Centers for Disease Control and Prevention.2011.2011 National Diabetes Fact Sheet. Accessed February 7 2012.http://www.cdc.gov/diabetes/pubs/factsheet11.htm.

2. Characteristics associated with poor glycemic control among adults with self‐reported diagnosed diabetes—national health and nutrition examination survey, United States, 2007–2010;Ali M.K.;MMWR Morb. Mortal. Wkly. Rep.,2012

3. The Burden of Chronic Hyperglycemia

4. Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach: Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes

5. Comparative Effectiveness and Safety of Medications for Type 2 Diabetes: An Update Including New Drugs and 2-Drug Combinations

Cited by 71 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A comprehensive review of small-molecule drugs for the treatment of type 2 diabetes mellitus: Synthetic approaches and clinical applications;European Journal of Medicinal Chemistry;2024-03

2. Canagliflozin reduces thyroid cancer cells migration in vitro by inhibiting CXCL8 and CCL2: An additional anti-tumor effect of the drug;Biomedicine & Pharmacotherapy;2024-01

3. Green sustainable assessment of stability indicating first derivative synchronous fluorimetry for determination of anti-diabetic drug with its toxic impurity;Sustainable Chemistry and Pharmacy;2023-12

4. Improved dissolution and pharmacokinetics of insufficiently water-soluble canagliflozin in solid dispersions with gelucire 50/13 as a drug carrier;2023-11-02

5. Role of canagliflozin in ameliorating isoprenaline induced cardiomyocyte oxidative stress via the heme oxygenase-1 mediated pathway;Biotechnic & Histochemistry;2023-10-02